Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice.

BACKGROUND: Doxorubicin (DOX) leads to cardiovascular toxicity through direct cardiomyocyte injury and inflammation. We aimed to study the role of Galectin-3 (Gal-3), a ß-galactosidase binding lectin associated with inflammation and fibrosis in DOX-induced acute cardiotoxicity in mice. METHODS: Male C57 and Gal-3 knockout (KO) mice were given a single dose of DOX (15 mg/kg, i.p) or placebo. Serum creatine phosphokinase (CPK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and cardiac thiobarbituric acid-reactive substance (TBARS) were measured at 3 days to assess cardiac injury and oxidative stress. Cardiac remodeling and function were studied by echocardiography and catheterization at 7 days. Myocardial fibrosis was quantified in picrosirius red stained slices. RESULTS: Absence of Gal-3 tended to reduce the mortality after DOX. DOX significantly increased CPK, LDH, AST and TBARS while treated Gal-3 KO mice showed reduced injury and oxidative stress. After 7 days, adverse remodeling, fibrosis and dysfunction in treated-C57 mice were severely affected while those effects were prevented by absence of Gal-3. CONCLUSION: In summary, genetic deletion of Gal-3 prevented cardiac damage, adverse remodeling and dysfunction, associated with reduced cardiac oxidative stress and fibrosis. Understanding the contribution of GAL-3 to doxorubicin-induced cardiac toxicity reinforces its potential use as a therapeutic target in patients with several cancer types.

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice.

Cardiovascular disease is the most prevalent cause of death in Western countries, with acute myocardial infarction (MI) being the most prevalent form. This paper describes a protocol for studying the role of galectin 3 (Gal-3) in the temporal evolution of cardiac healing and remodeling in an experimental animal model of MI. The procedures described include an experimental model of MI with a permanent coronary ligature in male C57BL/6J (control) and Gal-3 knockout (KO) mice, an echocardiography procedure to study cardiac remodeling and systolic function in vivo, a histological evaluation of interstitial myocardial fibrosis with picrosirius red-stained and rhodamine-conjugated lectin-stained sections for studying myocyte hypertrophy by the cross-sectional area (MCSA), and the quantification of infarct size and cardiac remodeling (scar thinning, septum thickness, and expansion index) by planimetry in slices stained with Masson's trichrome and triphenyl tetrazolium chloride. Gal-3 KO mice with MI showed disrupted cardiac remodeling and an increase in the scar thinning ratio and the expansion index. At the onset of MI, myocardial function and cardiac remodeling were also severely affected. At 4 weeks post MI, the natural evolution of fibrosis in infarcted Gal-3 KO mice was also affected. In summary, the experimental model of MI is a suitable model for studying the temporal evolution of cardiac repair and remodeling in mice with the genetic deletion of Gal-3 and other animal models. The lack of Gal-3 affects the dynamics of cardiac repair and disrupts the evolution of cardiac remodeling and function after MI.

Unraveling the role of galectin-3 in cardiac pathology and physiology.

Galectin-3 (Gal-3) is a carbohydrate-binding protein with multiple functions. Gal-3 regulates cell growth, proliferation, and apoptosis by orchestrating cell-cell and cell-matrix interactions. It is implicated in the development and progression of cardiovascular disease, and its expression is increased in patients with heart failure. In atherosclerosis, Gal-3 promotes monocyte recruitment to the arterial wall boosting inflammation and atheroma. In acute myocardial infarction (AMI), the expression of Gal-3 increases in infarcted and remote zones from the beginning of AMI, and plays a critical role in macrophage infiltration, differentiation to M1 phenotype, inflammation and interstitial fibrosis through collagen synthesis. Genetic deficiency of Gal-3 delays wound healing, impairs cardiac remodeling and function after AMI. On the contrary, Gal-3 deficiency shows opposite results with improved remodeling and function in other cardiomyopathies and in hypertension. Pharmacologic inhibition with non-selective inhibitors is also protective in cardiac disease. Finally, we recently showed that Gal-3 participates in normal aging. However, genetic absence of Gal-3 in aged mice exacerbates pathological hypertrophy and increases fibrosis, as opposed to reduced fibrosis shown in cardiac disease. Despite some gaps in understanding its precise mechanisms of action, Gal-3 represents a potential therapeutic target for the treatment of cardiovascular diseases and the management of cardiac aging. In this review, we summarize the current knowledge regarding the role of Gal-3 in the pathophysiology of heart failure, atherosclerosis, hypertension, myocarditis, and ischemic heart disease. Furthermore, we describe the physiological role of Gal-3 in cardiac aging.

Cardiac Natriuretic Peptide Profiles in Chronic Hypertension by Single or Sequentially Combined Renovascular and DOCA-Salt Treatments.

The involvement of natriuretic peptides was studied during the hypertrophic remodeling transition mediated by sequential exposure to chronic hemodynamic overload. We induced hypertension in rats by pressure (renovascular) or volume overload (DOCA-salt) during 6 and 12 weeks of treatment. We also studied the consecutive combination of both models in inverse sequences: RV 6 weeks/DS 6 weeks and DS 6 weeks/RV 6 weeks. All treated groups developed hypertension. Cardiac hypertrophy and left ventricular ANP gene expression were more pronounced in single DS than in single RV groups. BNP gene expression was positively correlated with left ventricular hypertrophy only in RV groups, while ANP gene expression was positively correlated with left ventricular hypertrophy only in DS groups. Combined models exhibited intermediate values between those of single groups at 6 and 12 weeks. The latter stimulus associated to the second applied overload is less effective than the former to trigger cardiac hypertrophy and to increase ANP and BNP gene expression. In addition, we suggest a correlation of ANP synthesis with volume overload and of BNP synthesis with pressure overload-induced hypertrophy after a prolonged treatment. Volume and pressure overload may be two mechanisms, among others, involved in the differential regulation of ANP and BNP gene expression in hypertrophied left ventricles. Plasma ANP levels reflect a response to plasma volume increase and volume overload, while circulating BNP levels seem to be regulated by cardiac BNP synthesis and ventricular hypertrophy.

Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.

ß-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprotection of traditional ß-blockers compared with other antihypertensive drugs. It is unknown whether third-generation ß-blockers share the limitations of traditional ß-blockers. The aim of the present study was to compare the effects of nebivolol or atenolol on central and peripheral systolic blood pressure (SBP) and its variability and target organ damage (TOD) in N-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Male Wistar rats were treated with L-NAME for 8 weeks together with oral administration of nebivolol 30 mg/kg (n = 8), atenolol 90 mg/kg (n = 8), or vehicle (n = 8). The control group was composed of vehicle-treated Wistar rats. SBP and its variability, as well as echocardiographic parameters, were assessed during the last 2 weeks of treatment. Tissue levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor ß (TGF-ß), and histopathological parameters were evaluated in the left ventricle and aorta. Nebivolol had a greater ability than atenolol to decrease central SBP and mid-term and short-term blood pressure variability (BPV) in L-NAME rats. Echocardiographic analysis showed that nebivolol was more effective than atenolol on E/A wave ratio normalization. Compared with atenolol treatment, nebivolol had a greater protective effect on different TOD markers, inducing a decrease in collagen deposition and a reduction in the proinflammatory cytokines IL-6 and TNF-α in the left ventricle and aorta. Our findings suggest that the adverse hemodynamic profile and the reduced cardiovascular protection reported with traditional ß-blockers must not be carried forward to third-generation ß-blockers.

Genetic Deletion of Galectin-3 Alters the Temporal Evolution of Macrophage Infiltration and Healing Affecting the Cardiac Remodeling and Function after Myocardial Infarction in Mice.

We studied the role of galectin-3 (Gal-3) in the expression of alternative activation markers (M2) on macrophage, cytokines, and fibrosis through the temporal evolution of healing, ventricular remodeling, and function after myocardial infarction (MI). C57BL/6J and Gal-3 knockout mice (Lgals3-/-) were subjected to permanent coronary ligation or sham. We studied i) mortality, ii) macrophage infiltration and expression of markers of alternative activation, iii) cytokine, iv) matrix metalloproteinase-2 activity, v) fibrosis, and vi) cardiac function and remodeling. At 1 week post-MI, lack of Gal-3 markedly attenuated F4/80+ macrophage infiltration and significantly increased the expression of Mrc1 and Chil1, markers of M2 macrophages at the MI zone. Levels of IL-10, IL-6, and matrix metalloproteinase-2 were significantly increased, whereas tumor necrosis factor-α, transforming growth factor-ß, and fibrosis were remarkably attenuated at the infarct zone. In Gal-3 knockout mice, scar thinning ratio, expansion, and cardiac remodeling and function were severely affected from the onset of MI. At 4 weeks post-MI, the natural evolution of fibrosis in Gal-3 knockout mice was also affected. Our results suggest that Gal-3 is essential for wound healing because it regulates the dynamics of macrophage infiltration, proinflammatory and anti-inflammatory cytokine expression, and fibrosis along the temporal evolution of MI in mice. The deficit of Gal-3 affected the dynamics of wound healing, thus aggravating the evolution of remodeling and function.

Effects of third-generation ß-blockers, atenolol or amlodipine on blood pressure variability and target organ damage in spontaneously hypertensive rats.

BACKGROUND: ß-blockers are no longer considered as first-line antihypertensive drugs due to their lower cardioprotection. METHOD: Considering the differences in the pharmacological properties of ß-blockers, the present work compared the effects of third-generation ß-blockers - carvedilol and nebivolol - with a first-line agent - amlodipine - on hemodynamic parameters, including short-term blood pressure variability (BPV), and their ability to prevent target organ damage in spontaneously hypertensive rats (SHR). SHR rats were orally treated with carvedilol, nebivolol, atenolol, amlodipine or vehicle for 8 weeks. Wistar Kyoto rats treated with vehicle were used as normotensive group. Echocardiographic evaluation, BP, and short-term BPV measurements were performed. Left ventricle and thoracic aorta were removed for histological evaluations and to assess the expression of transforming growth factor ß (TGF-ß), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). RESULTS: Carvedilol, nebivolol or amlodipine induced a greater reduction of carotid BP, short-term BPV and echocardiography parameters than atenolol in SHR rats. Carvedilol, nebivolol and amlodipine were more effective than atenolol in the prevention of cardiac hypertrophy, and cardiac and aortic collagen deposit. Carvedilol and nebivolol, but not atenolol, reduced the expressions of fibrotic and inflammatory biomarkers - TGF-ß, TNF-α and IL-6 - in SHR rats to a similar extent to that of amlodipine. CONCLUSION: Chronic treatment with carvedilol or nebivolol attenuates carotid BP and short-term BPV, and reduces target organ damage in SHR to a greater extent than atenolol. Our findings suggest that the lower cardiovascular protection of nonvasodilating ß-blockers, as atenolol, in hypertension must not be translated to third-generation ß-blockers.

Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities.

Galectin-1 (Gal-1), an evolutionarily conserved ß-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy, pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension.

Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.

The aim of the study was to compare the effects of chronic oral treatment with carvedilol or amlodipine on blood pressure, blood pressure variability and target organ damage in N-nitro-l-arginine methyl ester (L-NAME) hypertensive rats. Wistar rats were treated with L-NAME administered in the drinking water for 8 weeks together with oral administration of carvedilol 30 mg/kg (n = 6), amlodipine 10 mg/kg (n = 6), or vehicle (n = 6). At the end of the treatment, echocardiographic evaluation, blood pressure, and short-term variability measurements were performed. Left ventricular and thoracic aortas were removed to assess activity of metalloproteinase 2 and 9 and expression levels of transforming growth factor ß, tumor necrosis factor α, and interleukin 6. Histological samples were prepared from both tissues. Carvedilol and amlodipine induced a comparable reduction of systolic and mean arterial pressure and its short-term variability in L-NAME rats. The expression of transforming growth factor ß, tumor necrosis factor α, and interleukin 6 decreased in both organs after carvedilol or amlodipine treatment and the activity of metalloproteinase was reduced in aortic tissue. Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta. Oral chronic treatment with carvedilol or amlodipine significantly attenuates blood pressure variability and reduces target organ damage and biomarkers of tissue fibrosis and inflammation in L-NAME hypertensive rats.

Efecto de la administración de atenolol o nebivolol sobre la variabilidad de la presión arterial y su impacto sobre el daño de órgano blanco en ratas espontáneamente hipertensas / Effect of Atenolol or Nebivolol Administration on Blood Pressure Variability and its Impact on White Organ Damage in Spontaneously Hypertensive Rats

Introducción: Tradicionalmente se ha considerado que el riesgo cardiovascular asociado con la hipertensión es producto de la elevación sostenida de la presión arterial, que lleva al daño de órgano blanco. En los últimos años se ha descripto que otros factores, como la variabilidad de la presión arterial y la presión arterial central, también afectan directamente el daño de órgano blanco. Objetivo: Determinar los efectos de la administración crónica de atenolol o nebivolol sobre la variabilidad de la presión arterial a corto plazo y el daño de órgano blanco a nivel del ventrículo izquierdo y de la aorta. Material y métodos: Se incluyeron ratas espontáneamente hipertensas (REH) que fueron tratadas durante 8 semanas con una única administración diaria de atenolol, nebivolol o vehículo. Se determinaron la presión arterial y su variabilidad a corto plazo y se realizó ecocardiografía. Se extrajeron el ventrículo izquierdo y la aorta torácica para cuantificar la expresión del factor de crecimiento transformante b y realizar estudios histológicos. Resultados: El tratamiento crónico con nebivolol redujo la presión arterial media (PAM) y su variabilidad en mayor medida que el atenolol (PAM WKY: 118,6 ± 8,0 mm Hg; REH: 174,6 ± 2,1ª mm Hg; REH-atenolol: 155,2 ± 2,1a, b mm Hg; REH-nebivolol: 122,3 ± 2,3b, c mm Hg; desviación estándar de la PAM WKY: 3,8 ± 0,2 mm Hg; REH: 6,2 ± 0,3ª mm Hg; REH-atenolol: 5,2 ± 0,3a, b mm Hg; REH-nebivolol: 4,2 ± 0,2b, c mm Hg; ªp < 0,05 vs. ratas WKY; b p < 0,05 vs. REH; c p < 0,05 vs. REH-atenolol). Conclusiones: El análisis del daño de órgano blanco establece que el nebivolol reduce el contenido de fibrosis ventricular, disminuye el espesor de la media aórtica e induce una mayor reducción de la sobreexpresión del factor de crecimiento transformante b en ambos órganos en comparación con REH tratadas con vehículo o atenolol. Estos hallazgos sugieren que la mayor reducción de la presión arterial central, junto con la disminución de la labilidad de la presión arterial, contribuiría en la superior protección del daño de órgano blanco por el nebivolol respecto del atenolol.

Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension.

Galectin-3 (Gal-3), a member of the ß-galactoside lectin family, has an important role in immune regulation. In hypertensive rats and heart failure patients, Gal-3 is considered a marker for an unfavorable prognosis. Nevertheless, the role and mechanism of Gal-3 action in hypertension-induced target organ damage are unknown. We hypothesized that, in angiotensin II (ANG II)-induced hypertension, genetic deletion of Gal-3 prevents left ventricular (LV) adverse remodeling and LV dysfunction by reducing the innate immune responses and myocardial fibrosis. To induce hypertension, male C57BL/6J and Gal-3 knockout (KO) mice were infused with ANG II (3 µg·min-1·kg-1 sc) for 8 wk. We assessed: 1) systolic blood pressure by plethysmography, 2) LV function and remodeling by echocardiography, 3) myocardial fibrosis by histology, 4) cardiac CD68+ macrophage infiltration by histology, 5) ICAM-1 and VCAM-1 expression by Western blotting, 6) plasma cytokines, including interleukin-6 (IL-6), by enzyme-linked immunosorbent assay, and 7) regulatory T (Treg) cells by flow cytometry as detected by their combined expression of CD4, CD25, and FOXP3. Systolic blood pressure and cardiac hypertrophy increased similarly in both mouse strains when infused with ANG II. However, hypertensive C57BL/6J mice suffered impaired ejection and shortening fractions. In these mice, the extent of myocardial fibrosis and macrophage infiltration was greater in histological sections, and cardiac ICAM-1, as well as plasma IL-6, expression was higher as assessed by Western blotting. However, all these parameters were blunted in Gal-3 KO mice. Hypertensive Gal-3 KO mice also had a higher number of splenic Treg lymphocytes. In conclusion, in ANG II-induced hypertension, genetic deletion of Gal-3 prevented LV dysfunction without affecting blood pressure or LV hypertrophy. This study indicates that the ANG II effects are, in part, mediated or triggered by Gal-3 together with the related intercellular signaling (ICAM-1 and IL-6), leading to cardiac inflammation and fibrosis.

Early administration of Enalapril prevents diastolic dysfunction and ventricular remodeling in rabbits with myocardial infarction.

We aimed to investigate the role of early administration of Enalapril (Enal) on post-myocardial infarction (MI) ventricular remodeling and diastolic dysfunction in rabbits. White New Zealand rabbits that underwent coronary artery ligature or Sham were divided in three experimental groups: (1) Sham, (2) MI, and (3) MI+Enal. Enal was given by gavage at a dose of 10mg/kg/day starting at 3h after surgery for 35days. At the end of the protocol, we measured (1) mean arterial pressure, (2) left ventricular (LV)+dP/dtmax, (3) LV end-diastolic pressure (LVEDP) and isovolumic relaxation (Tau), (4) LV dimensions, (5) LV ejection and shortening fraction, (6) infarct size (Masson's trichrome-stained slices), (7) fibrosis in the infarct and remote zone (Picrosirius red-stained slices), and (8) myocyte cross-sectional area (MCSA) in WGA-stained section. Enal reduced the mean arterial pressure by 30% as compared with untreated animals and Sham (P<.05). MI reduced LV+dP/dtmax and LV-dP/dtmax (mmHg/s), increased LVEDP (mmHg), Tau (ms), and t50 (ms) values, suggesting a decrease in the relaxation rate. LV end-diastolic dimension and LV end-systolic dimension (LVESD, mm) increased in untreated MI (P<.05 vs. Sham). In contrast, Enal markedly prevented post-MI diastolic dysfunction by significantly decrease LVEDP from 8.2±0.2 to 5.1±0.3mmHg, Tau from 19.8±0.8 to 15.3±0.9ms, and t50 from 12.4±0.5 to 9.6±0.8ms as well as reduced LVESD from 15±1.1 to 12±0.8mm (P<.05 MI vs. MI+Enal). Collagen concentration in the scar was unaffected, but chronic treatment with Enal prevented myocardial fibrosis and MCSA in the remote zone. In summary, chronic early administration of Enal to rabbits with experimental MI has a favorable effect on ventricular remodeling and diastolic function by reducing MCSA and fibrosis, without affecting the wound healing.

Effects of Endurance Training on Myocardial Hypertrophy and Ventricular Function in a Transgenic Mouse Model with sympathetic Hyperactivity / Efectos del ejercicio intenso sobre la hipertrofia miocárdica y la función ventricular en un modelo de ratón transgénico con hiperactividad simpática

Background: Previous studies have shown that endurance training (ET) reduces inotropic, chronotropic and lusitropic reserve in normal mice. Objective: The aim of this study was to evaluate the effect of endurance training on the inotropic and chronotropic reserve of trans-genic mice with sympathetic hyperactivity induced by overexpression of the cardiac GSα protein. Methods: Endurance training consisted in two daily 90-min sessions, 6 days/week, during 4 weeks. Four experimental groups were formed: 1) non-transgenic sedentary (nonTG Sed); 2) transgenic sedentary (TG Sed); 3) nonTG+ET and 4) TG+ET. Results: Endurance training induced myocardial hypertrophy [left ventricular weight (g)/tibial length (mm)] from 5.3±0.3 and 5.5±0.2 in nonTG Sed and TG Sed to 6.8±0.1 and 6.8±0.3 in nonTG+ET and TG+ET, respectively (p<0.05 nonTG Sed vs. nonTG+ET and TG Sed vs. TG+ET). Isoproterenol administration (56 ng/kg) increased +dP/dtmax by 63±10% in nonTG Sed (p<0.05 vs. baseline), 34±2% in TG Sed (p<0.05 vs. baseline and p<0.05 vs. nonTG Sed), 36±7% in non TG+ET (p<0.05 vs. base-line) and 36±7% in TG+ET (p<0.05 vs. baseline). Heart rate (beats/min) increased from 301±15 to 528±37 in nonTG Sed (p<0.05 vs. baseline), from 519±57 to 603±41 in TG Sed, from 300±16 to 375±20 in nonTG+ET (p<0.05 vs. baseline) and from 484±18 to 515±21 in TG+ET. Interstitial collagen was similar among groups. Conclusions: These results suggest that endurance training decreases inotropic and chronotropic reserve without generating struc-tural changes associated to pathological hypertrophy. The presence of sympathetic hyperactivity does not modify this response.

Introducción: En estudios previos mostramos que el ejercicio intenso (EI) reduce la reserva inotrópica, cronotrópica y lusitrópica en ratones normales. Objetivo: Evaluar el efecto del ejercicio intenso sobre la reserva inotrópica y cronotrópica en un modelo de ratones transgénicos con sobreexpresión cardíaca de la proteína Gsα, que induce un cuadro de hiperactividad simpática. Material y métodos: El ejercicio consistió en dos sesiones diarias de 90 minutos de natación, 6 días/semana durante 4 semanas. Se utilizaron cuatro grupos experimentales: 1: sedentario no transgénico (noTG Sed); 2: sedentario TG (TG Sed); 3: noTG+EI y 4: TG+EI. Resultados: El ejercicio indujo el desarrollo de hipertrofia miocárdica [índice peso del ventrículo izquierdo (g)/longitud de la tibia (mm)] desde 5,3±0,3 y 5,5±0,2 en noTG Sed y TG Sed a 6,8±0,1 y 6,8±0,3 en noTG+EI y TG+EI, respectivamente (p<0,05 noTG Sed vs. noTG+EI y TG Sed vs. TG+EI). La administración de isoproterenol (56 ng/kg) incrementó la +dP/dtmáx 63% ±10% en noTG Sed (p<0,05 vs. basal); 34% ±2% en TG Sed (p<0,05 vs.basal y p< 0,05 vs. noTG Sed); 36% ±7% en noTG+EI (p<0,05 vs. basal) y 36% ±7% en TG+EI (p<0,05 vs.basal). La frecuencia cardíaca aumentó de 301±15 a 528±37 latidos/min en noTG Sed (p<0,05 vs. basal), de 519±57 a 603±41 latidos/min en TG Sed, de 300±16 a 375±20 en noTG+EI (p<0,05 vs. basal) y de 484±18 a 515±21 en TG+EI. El colágeno intersticial fue similar entre los grupos. Conclusiones: Estos resultados sugieren que el ejercicio intenso disminuye la reserva inotrópica y cronotrópica sin generar cambios estructurales vinculados a la hipertrofia patológica. La presencia de hiperactividad simpática no modifica esta respuesta.

Efecto del déficit de galectina-3 sobre la remodelación ventricular posoclusión coronaria en ratones / Effect of Galectin-3 Deficit on Ventricular Remodeling After Coronary Occlusion in Mice

Introducción: La galectina-3 (Gal-3) es una lectina que regula la respuesta inmune. Sin embargo, su rol en la remodelación y la función ventricular posinfarto de miocardio (IM) se desconoce. Objetivo: Estudiar si el déficit de Gal-3 empeora la remodelación y la función ventricular pos-IM en ratones. Material y métodos: Se utilizaron ratones machos Gal-3 KO y su respectivo control C57 con ligadura de la coronaria descendente anterior o sham. Se conformaron cuatro grupos experimentales: C57 sham, Gal-3 KO sham, C57 IM y Gal-3 KO IM. A los 7 días poscirugía se les realizó ecocardiografía seguida de eutanasia y autopsia; se cuantificó el tamaño del IM y la fibrosis en cortes teñidos con tricrómico de Masson y picrosirius red, respectivamente, el infiltrado de macrófagos y la expresión de IL-6. Resultados: Los diámetros del ventrículo izquierdo se incrementaron significativamente en el grupo C57 IM respecto del sham y dicho incremento fue aún mayor en el grupo Gal-3 KO IM. Además, la fracción de eyección disminuyó desde 47% ± 2% a 37% ± 3% en C57 IM y Gal-3 KO IM, respectivamente (p < 0,02). El tamaño del IM aumentó desde 39,4% ± 5% en los ratones C57 IM a 66,8% ± 5% en los animales Gal-3 KO (p = 0,002). El infiltrado de macrófagos y la fibrosis en el área del IM se redujeron en los ratones Gal-3 KO IM (p < 0,001 C57 IM vs. Gal-3 KO IM), mientras que la concentración de IL-6 en la pared libre del ventrículo izquierdo fue similar entre grupos (p = ns). Conclusiones: La deleción de Gal-3 es un factor importante para la cinética del proceso reparativo regulando el infiltrado de macrófagos y el grado de fibrosis de la zona infartada, como también en la evolución temprana de la remodelación pos-IM.

Background: Galectin-3 (Gal-3) is a lectin that regulates the immune response. However, its role in remodeling and ventricular function after myocardial infarction (MI) is unknown. Objective: The purpose of this study was to analyze whether Gal-3 deficit impairs remodeling and ventricular function after MI in mice. Methods: Male Gal-3 KO mice and their respective C57 controls underwent anterior descending coronary artery ligation or sham operation. Animals were then divided into four experimental groups: 1) C57 sham; 2) Gal-3 KO sham; 3) C57 MI and 4) Gal-3 KO MI. Seven days after surgery, an echocardiography was performed followed by euthanasia. Heart samples were collected to measure MI size and fibrosis using Masson's trichrome and picrosirius red, respectively, and assess macrophage infiltration and IL-6 expression. Results: Left ventricular diameters were significantly increased in the C57 MI group compared with sham animals and the increase was even higher in the Gal-3 KO MI group. Moreover, ejection fraction decreased to 47%±2% in C57 MI and 37%±3% in Gal-3 KO MI mice (p<0.02), and infarct size increased from 39.4%±5% in C57 MI to 66.8%±5% in Gal-3 KO MI animals (p=0.002). Macrophage infiltration and fibrosis in the MI area were significantly reduced in Gal-3 KO MI mice (p<0.001 C57 MI vs. Gal-3KO MI) without changes of IL-6 concentration in the left ventricular free wall (p=ns). Conclusions: Gal-3 gene deletion is an important factor in repair kinetics, regulating macrophage infiltration and the degree of fibrosis in the infarct area, as well as early remodeling after MI.

Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension.

OBJECTIVE: Inflammation has been proposed as a key component in the development of hypertension and cardiac remodeling associated with different cardiovascular diseases. However, the role of the proinflammatory cytokine interleukin-6 in the chronic stage of hypertension is not well defined. Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II). METHODS: Male C57BL/6J and interleukin-6-knock out (KO) mice were implanted with telemetry devices for blood pressure (BP) measurements, fed a 4% NaCl diet, and infused with either vehicle or Ang II (90 ng/min per mouse subcutaneously) for 8 weeks. We studied BP and cardiac function by echocardiography at baseline, 4 and 8 weeks. RESULTS: Myocyte cross-sectional area (MCSA), macrophage infiltration, and myocardial fibrosis were also assessed. BP increased similarly in both strains when treated with Ang II and high salt (Ang II-high salt); however, C57BL/6J mice developed a more severe decrease in left ventricle ejection fraction, fibrosis, and macrophage infiltration compared with interleukin-6-KO mice. No differences between strains were observed in MCSA, capillary density and MCSA to capillary density ratio. CONCLUSION: In conclusion, absence of interleukin -6 did not alter the development of Ang II-high salt-induced hypertension and cardiac hypertrophy, but it prevented the development of cardiac dysfunction, myocardial inflammation, and fibrosis. This indicates that interleukin-6 plays an important role in hypertensive heart damage but not in the development of hypertension.

N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats.

We have reported previously that Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) reduces fibrosis and inflammation (in macrophages and mast cells). However, it is not known whether Ac-SDKP decreases collagen cross-linking and lymphocyte infiltration; lymphocytes modulate both collagen cross-linking and ECM (extracellular matrix) formation in hypertension. Thus we hypothesized that (i) in AngII (angiotensin II)-induced hypertension, Ac-SDKP prevents increases in cross-linked and total collagen by down-regulating LOX (lysyl oxidase), the enzyme responsible for cross-linking, and (ii) these effects are associated with decreased pro-fibrotic cytokine TGFß (transforming growth factor ß) and the pro-inflammatory transcription factor NF-κB (nuclear factor κB) and CD4+/CD8+ lymphocyte infiltration. We induced hypertension in rats by infusing AngII either alone or combined with Ac-SDKP for 3 weeks. Whereas Ac-SDKP failed to lower BP (blood pressure) or LV (left ventricular) hypertrophy, it did prevent AngII-induced increases in (i) cross-linked and total collagen, (ii) LOX mRNA expression and LOXL1 (LOX-like 1) protein, (iii) TGFß expression, (iv) nuclear translocation of NF-κB, (v) CD4+/CD8+ lymphocyte infiltration, and (vi) CD68+ macrophages infiltration. In addition, we found a positive correlation between CD4+ infiltration and LOXL1 expression. In conclusion, the effect of Ac-SDKP on collagen cross-linking and total collagen may be due to reduced TGFß1, LOXL1, and lymphocyte and macrophage infiltration, and its effect on inflammation could be due to lower NF-κB.

Efectos del ejercicio intenso sobre la función ventricular basal y la respuesta inotrópica, cronotrópica y lusitrópica en ratones / Effects of Strenuous Exercise on Baseline Ventricular Function and Inotropic, Chronotropic and Lusitropic Response in Mice

Introducción El ejercicio leve a moderado reduce los factores de riesgo cardiovascular, mejora estados patológicos previamente establecidos y produce el desarrollo de hipertrofia cardíaca adaptativa. Sin embargo, la respuesta del miocardio frente a un tipo de ejercicio intenso no es del todo conocida. Objetivo Estudiar la función ventricular basal y la reserva miocárdica (respuesta inotrópica, cronotró-pica y lusitrópica frente a un agonista ß-adrenérgico como el isoproterenol) luego de un tipo de ejercicio intenso tanto in vivo como in vitro en ratones. Material y métodos Se utilizaron ratones macho de tres meses de edad de la cepa FVB. El protocolo de ejercicio consistió en dos sesiones diarias de 90 minutos de natación, 6 días/semana durante 4 semanas. Se conformaron dos grupos experimentales: 1) Sedentario: no realiza ejercicio y 2) Ejercicio: realiza protocolo completo de natación intenso. Resultados Al finalizar el protocolo hubo un incremento de la masa ventricular izquierda del 27,9% ± 4%, con función ventricular basal conservada. Sin embargo, hubo una disminución de la respuesta miocárdica al isoproterenol tanto in vivo como in vitro, sin observarse modificaciones en el colágeno intersticial. Conclusiones En nuestras condiciones experimentales, el protocolo de natación, con características de ejercicio intenso, produjo una hipertrofia cardíaca moderada con características mixtas de hipertrofia adaptativa y no adaptativa. Si bien la función basal se mantuvo conservada y no hubo cambios en el colágeno intersticial, se observó una disminución en la reserva inotrópica, cronotrópica y lusitrópica.

Mild to moderate exercise reduces cardiovascular risk factors, improves pre-existing pathologic conditions and develops adaptive cardiac hypertrophy. However, the myocardial response to strenuous exercise is scarcely known. Objective The aim of this study was to evaluate baseline ventricular function and myocardial reserve (inotropic, chronotropic and lusitropic response to the ß-adrenergic agonist isoproterenol) in vivo and in vitro in mice following strenuous exercise. Methods Adult male FVB mice (3 months old) were used. The protocol exercise consisted in 90 min swimming sessions twice a day, 6 days/week for 4 weeks. Two experimental groups were evaluated: 1) sedentary group, with no exercise; and 2) exercise group, with full strenuous swimming protocol. Results At the end of the protocol, left ventricular mass increased by 27.9±4% with preserved baseline left ventricular function. In vivo and in vitro myocardial response to isoproterenol decreased with no changes in interstitial collagen. Conclusions Under our experimental conditions, a strenuous swimming protocol produced moderate cardiac hypertrophy with adaptive and maladaptive hypertrophic characteristics. Although baseline ventricular function was preserved with no changes in interstitial collagen, inotropic, chronotropic and lusitropic reserve decreased.

Efectos del ejercicio intenso sobre la función ventricular basal y la respuesta inotrópica, cronotrópica y lusitrópica en ratones / Effects of Strenuous Exercise on Baseline Ventricular Function and Inotropic, Chronotropic and Lusitropic Response in Mice

Introducción El ejercicio leve a moderado reduce los factores de riesgo cardiovascular, mejora estados patológicos previamente establecidos y produce el desarrollo de hipertrofia cardíaca adaptativa. Sin embargo, la respuesta del miocardio frente a un tipo de ejercicio intenso no es del todo conocida. Objetivo Estudiar la función ventricular basal y la reserva miocárdica (respuesta inotrópica, cronotró-pica y lusitrópica frente a un agonista ß-adrenérgico como el isoproterenol) luego de un tipo de ejercicio intenso tanto in vivo como in vitro en ratones. Material y métodos Se utilizaron ratones macho de tres meses de edad de la cepa FVB. El protocolo de ejercicio consistió en dos sesiones diarias de 90 minutos de natación, 6 días/semana durante 4 semanas. Se conformaron dos grupos experimentales: 1) Sedentario: no realiza ejercicio y 2) Ejercicio: realiza protocolo completo de natación intenso. Resultados Al finalizar el protocolo hubo un incremento de la masa ventricular izquierda del 27,9% ± 4%, con función ventricular basal conservada. Sin embargo, hubo una disminución de la respuesta miocárdica al isoproterenol tanto in vivo como in vitro, sin observarse modificaciones en el colágeno intersticial. Conclusiones En nuestras condiciones experimentales, el protocolo de natación, con características de ejercicio intenso, produjo una hipertrofia cardíaca moderada con características mixtas de hipertrofia adaptativa y no adaptativa. Si bien la función basal se mantuvo conservada y no hubo cambios en el colágeno intersticial, se observó una disminución en la reserva inotrópica, cronotrópica y lusitrópica.(AU)

Mild to moderate exercise reduces cardiovascular risk factors, improves pre-existing pathologic conditions and develops adaptive cardiac hypertrophy. However, the myocardial response to strenuous exercise is scarcely known. Objective The aim of this study was to evaluate baseline ventricular function and myocardial reserve (inotropic, chronotropic and lusitropic response to the ß-adrenergic agonist isoproterenol) in vivo and in vitro in mice following strenuous exercise. Methods Adult male FVB mice (3 months old) were used. The protocol exercise consisted in 90 min swimming sessions twice a day, 6 days/week for 4 weeks. Two experimental groups were evaluated: 1) sedentary group, with no exercise; and 2) exercise group, with full strenuous swimming protocol. Results At the end of the protocol, left ventricular mass increased by 27.9±4% with preserved baseline left ventricular function. In vivo and in vitro myocardial response to isoproterenol decreased with no changes in interstitial collagen. Conclusions Under our experimental conditions, a strenuous swimming protocol produced moderate cardiac hypertrophy with adaptive and maladaptive hypertrophic characteristics. Although baseline ventricular function was preserved with no changes in interstitial collagen, inotropic, chronotropic and lusitropic reserve decreased.(AU)

Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction.

Galectin-1 (Gal-1), an evolutionarily conserved ß-galactoside-binding lectin, plays essential roles in the control of inflammation and neovascularization. Although identified as a major component of the contractile apparatus of cardiomyocytes, the potential role of Gal-1 in modulating heart pathophysiology is uncertain. Here, we aimed to characterize Gal-1 expression and function in the infarcted heart. Expression of Gal-1 was substantially increased in the mouse heart 7 days after acute myocardial infarction (AMI) and in hearts from patients with end-stage chronic heart failure. This lectin was localized mainly in cardiomyocytes and inflammatory infiltrates in peri-infarct areas, but not in remote areas. Both simulated hypoxia and proinflammatory cytokines selectively up-regulated Gal-1 expression in mouse cardiomyocytes, whereas anti-inflammatory cytokines inhibited expression of this lectin or had no considerable effect. Compared with their wild-type counterpart, Gal-1-deficient (Lgals1(-/-)) mice showed enhanced cardiac inflammation, characterized by increased numbers of macrophages, natural killer cells, and total T cells, but reduced frequency of regulatory T cells, leading to impaired cardiac function at baseline and impaired ventricular remodeling 7 days after nonreperfused AMI. Treatment of mice with recombinant Gal-1 attenuated cardiac damage in reperfused AMI. Taken together, our results indicate a protective role for Gal-1 in normal cardiac homeostasis and postinfarction remodeling by preventing cardiac inflammation. Thus, Gal-1 treatment represents a potential novel strategy to attenuate heart failure in AMI.